Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

VTD (Bortezomib Plus Thalidomide Plus Dexamethasone) Followed By Autologous Stem Cell Transplantation As First Line Treatment for Multiple Myeloma: Real Life Results from a Single Institution

Salvatore Palmieri, Angela Gravetti, Stefano Rocco, Antonella Carbone, Carolina Copia, Giuseppe Monaco, Cira Riccardi, Fioravante Ronconi, Felicetto Ferrara

Blood (2015) 126 (23): 5380.

https://doi.org/10.1182/blood.V126.23.5380.5380

Published: 2015

Journal Articles

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Angela Gravetti, Giuseppe Monaco, Carolina Copia, Salvatore Palmieri, Fioravante Ronconi, Stefano Rocco, Felicetto Ferrara

Blood (2015) 126 (23): 5300.

https://doi.org/10.1182/blood.V126.23.5300.5300

Published: 2015

Journal Articles

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Antonio Abbadessa, Salvatore Iaccarino, Giuseppe Monaco, Maria Luigia Vigliotti, Mario Troiano, Enrico Attingenti

Blood (2008) 112 (11): 4831.

https://doi.org/10.1182/blood.V112.11.4831.4831

Published: 2008

Journal Articles

Long Term Disease Free Survival in Patient with Linfoplasmocytic Lymphoma and Regression of Associated Severe Renal Failure after Treatment with Bortezomib.

Antonio Abbadessa, Giuseppe Monaco, Mario Troiano, Lucia Liguori, Elisa Focarile, Maria Luigia Vigliotti, Salvatore Iaccarino

Blood (2007) 110 (11): 4477.

https://doi.org/10.1182/blood.V110.11.4477.4477

Published: 2007

Journal Articles

Bcr-Abl-Mediated Suppression of Normal Hematopoiesis in Chronic Myeloid Leukemia: Involvement of a Modified Form of NGAL.

Hui Lin, MD, Xiaohong Leng, PhD, Tong Sun, MS, Giuseppe Monaco, MD, Clifton Stephens, DVM, PhD, John Belmont, MD, PhD, Ralph Arlinghaus, PhD

Blood (2005) 106 (11): 2869.

https://doi.org/10.1182/blood.V106.11.2869.2869

Published: 2005

NARROW

VTD (Bortezomib Plus Thalidomide Plus Dexamethasone) Followed By Autologous Stem Cell Transplantation As First Line Treatment for Multiple Myeloma: Real Life Results from a Single Institution

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Long Term Disease Free Survival in Patient with Linfoplasmocytic Lymphoma and Regression of Associated Severe Renal Failure after Treatment with Bortezomib.

Bcr-Abl-Mediated Suppression of Normal Hematopoiesis in Chronic Myeloid Leukemia: Involvement of a Modified Form of NGAL.

Email alerts

ASH Publications

American Society of Hematology

VTD (Bortezomib Plus Thalidomide Plus Dexamethasone) Followed By Autologous Stem Cell Transplantation As First Line Treatment for Multiple Myeloma: Real Life Results from a Single Institution

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Long Term Disease Free Survival in Patient with Linfoplasmocytic Lymphoma and Regression of Associated Severe Renal Failure after Treatment with Bortezomib.

Bcr-Abl-Mediated Suppression of Normal Hematopoiesis in Chronic Myeloid Leukemia: Involvement of a Modified Form of NGAL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only